We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01169792
First Posted: July 26, 2010
Last Update Posted: July 26, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Inje University
Information provided by:
Yonsei University
  Purpose

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen.

The investigators want to

  • evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and
  • analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Condition Intervention
Breast Neoplasms Survival Analysis Antineoplastic Agents Therapeutic Uses Drug: tamoxifen

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment

Resource links provided by NLM:


Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients
  • The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients
  • The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients

Secondary Outcome Measures:
  • The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy
  • The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy
  • The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy

Biospecimen Retention:   Samples With DNA
Blood samples with DNA

Groups/Cohorts Assigned Interventions
Breast cancer patients
Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
Drug: tamoxifen

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Breast cancer survivors who underwent surgery at Severance hospital, Yonsei University Health System.
Criteria

Inclusion Criteria:

  • age ≥ 18 years
  • Breast cancer patients who underwent surgery

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01169792


Locations
Korea, Republic of
Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine
Jin-Gu, Busan, Korea, Republic of, , 614-735
Department of Surgery, Yonsei University College of Medicine
Saedaemoon-gu, Seoul, Korea, Republic of, 120-752
Sponsors and Collaborators
Yonsei University
Inje University
Investigators
Study Chair: Byeong-Woo Park, M.D.,ph.D. Department of Surgery and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine
Study Chair: Jae-Gook Shin, M.D.,ph.D. Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine
  More Information

ClinicalTrials.gov Identifier: NCT01169792     History of Changes
Other Study ID Numbers: 4-2009-0483
First Submitted: July 23, 2010
First Posted: July 26, 2010
Last Update Posted: July 26, 2010
Last Verified: October 2009

Keywords provided by Yonsei University:
Tamoxifen
Cytochrome P-450 CYP2D6
Polymorphism
Single nucleotide
Antineoplastic Agents, Hormonal

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Tamoxifen
Antineoplastic Agents, Hormonal
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents